Gallium Compounds Binding Calcified Lesions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for atherosclerosis do not effectively address the inflammation at the calcified lesion stage, and there is no reliable method to target intermediate stages of the disease, with existing therapies mainly focusing on reducing LDL availability to slow plaque growth rather than directly addressing the inflammatory process.
Innovation Solution
Administration of a therapeutically effective amount of a pharmaceutically acceptable gallium compound to an arterial inflammation site with microcalcifications, where gallium ions bind to the calcium hydroxyapatite structure, disrupting further calcification and reducing inflammation, thereby preventing the progression of atherosclerotic lesions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments focus on reducing LDL availability to slow plaque growth, then plaque growth is slowed, but the inflammation at the calcified lesion stage is not effectively addressed
Solution Approach 1:
The patent changes the therapeutic parameter from LDL-lowering to direct anti-inflammatory action at the lesion site. Gallium compounds are administered to target the calcified lesion directly, changing the mechanism of action from systemic lipid management to localized inflammatory modulation, thereby addressing the intermediate stage that previous treatments could not effectively target
Solution Approach 2:
Gallium compounds serve as an intermediary agent that bridges the gap between conventional LDL-lowering therapies and the need for direct anti-inflammatory action. The gallium compounds accumulate at the lesion site and mediate the anti-inflammatory effect by modulating macrophage activity and reducing cytokine production, providing a targeted approach that previous treatments lacked
2Reliability
If gallium compounds are administered to bind calcified lesions, then inflammation is reduced and plaque growth is halted, but the frequency and dosage requirements need to be optimized
Solution Approach 1:
The patent establishes continuous useful action by demonstrating that gallium compounds provide sustained anti-inflammatory effects at the lesion site. The compounds accumulate in the calcified plaque and maintain therapeutic concentrations over time, providing ongoing anti-inflammatory action that reduces the need for frequent dosing and creates a continuous protective effect against plaque progression
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The gallium compound effectively binds to calcified lesions, reducing inflammation and halting the growth of atherosclerotic plaques, providing a long-lasting treatment that can be administered concurrently with standard therapies, with potential for reduced frequency of application due to sustained anti-inflammatory effects.
Implementation Method 1
gallium ions bind to the calcium hydroxyapatite structure, disrupting further calcification and reducing inflammation
Data Source
AI summary
The method for treating cardiovascular disease relates to stopping growth of an atherosclerotic plaque or lesion. A therapeutically effective amount of a pharmaceutically acceptable gallium compound is administered to an inflammation site in an artery with a lesion with microcalcifications. Gallium ions bind to the lesion. The proper amount of gallium compound delivered to the lesion disrupts a calcification process at the inflammation site. The gallium ions bind to calcium hydroxyapatites in microcalcifications so that the microcalcifications can no longer differentiate into early phase osteoblasts. The gallium integrated into the calcium structures at the inflammation site has a lasting effect to reduce atherosclerotic plaques.